Journals / MN Oftalmoloji / 2017 / Cilt: 24 - Sayı: 4

Results of Dexamethasone Implant in the Treatment of Retinal Vein Occlussion Related Macular Edema

Retina Ven Tıkanıklıklarına İkincil Maküla Ödemi Tedavisinde Deksametazon İmplant Sonuçları

Pages
226–231
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Dexamethasone implant was effective in improving best corrected visual acuity and central macular thickness in patients with branch retinal vein occlusion and central retinal vein occlusion in clinical practice. dexamethasone implant was well tolerated and had an acceptable safety profile.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To evaluate one year results of dexamethasone implants in the treatment of macular edema related to retinal vein occlusion.
📊
Key Findings & Data:Material and Method: This retrospective, observational study conducted in our hospital enrolled 47 patiens (47 eyes) diagnosed with macular edema following branch retinal vein occlusion or central retinal vein occlusion who were given dexamethasone implant.
💡
Conclusion & Impact:Conclusion: Dexamethasone implant was effective in improving best corrected visual acuity and central macular thickness in patients with branch retinal vein occlusion and central retinal vein occlusion in clinical practice. dexamethasone implant was well tolerated and had an acceptable safety profile.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To evaluate one year results of dexamethasone implants in the treatment of macular edema related to retinal vein occlusion. Material and Method: This retrospective, observational study conducted in our hospital enrolled 47 patiens (47 eyes) diagnosed with macular edema following branch retinal vein occlusion or central retinal vein occlusion who were given dexamethasone implant. Patients were evaluated by the best corrected visual acuity, optical cohorens tomograph and intraocular pressure recordings at the first, 4,8,12,24,36 and 48th week visits retrospectively. Results: The mean best corrected visual acuity (logMAR) level increased from 0.23±0.11 to 0.64±0.18 in the 8th week and was enrolled 0.55±0.17 in the 48th week (p<0.001). The mean central macular thickness was found at the first, 48th visits 507.7±24.9 µm, 251.8±25.5 µm, respectively (p<0.001). The initial mean intraocular pressure was 14.9 ± 2.7, 15.3 ± 3.3 mmHg at 24th week and 15.6 ± 3.1 mmHg at 48th week. There was no statistically significant difference between first and the other visits (p> 0.05). When the phakic and nonphakic patients were evaluated separately, there was a difference in favor of the nonphakic group on the mean of best corrected visual acuity after the 12th week (p <0.001). Conclusion: Dexamethasone implant was effective in improving best corrected visual acuity and central macular thickness in patients with branch retinal vein occlusion and central retinal vein occlusion in clinical practice. dexamethasone implant was well tolerated and had an acceptable safety profile.

Özet

Amaç: Retina ven oklüzyonu ile ilişkili maküler ödem tedavisinde deksametazon implantın 1 yıllık sonuçlarını değerlendirmeyi amaçladık. Gereç ve Yöntem: Bu retrospektif gözlemsel çalışmada santral retina ven oklüzyonu ve retina ven dal oklüzyonu ile ilişkili maküler ödemde hastanemize başvurmuş ve deksametazon implant tedavisi uygulanmış 47 hastanın (47 göz) dosyaları tarandı. Dosyalardan en iyi düzeltilmiş görme keskinliği, optik koherans tomografi ve göz içi basıncı ölçümü kayıtları retrospektif olarak başlangıç, 4,8,12,24,36 ve 48. haftalardaki vizitlerden temin edildi. Bulgular: Ortalama görme keskinliği (logMAR) 0,23±0,11 seviyesinden 0,64±0,18 seviyesine artış göstermiş ve 48. haftada bu değer 0,55± 0,17 olarak kaydedilmiştir (p 0,05) Fakik olan ve olmayan hastalar ayrı ayrı değerlendirildiğinde görme keskinliği ortalamalarında 12. haftadan sonra fakik olmayangrup lehine fark saptanmıştır (p<0,001).Sonuç: Klinik pratikte deksametazon implant uygulaması santral retina ven oklüzyonu ve retina ven dal oklüzyonu ile ilişkili maküler ödemde hem görme keskinliği hem de santral maküler kalınlıkta etkili bir düzelme sağlamıştır. Ayrıca deksametazon implant tolere edilebilir ve kabul edilebilir bir güvenlik profiline sahiptir.

🔖

Cite This Article

ÖZER, M. A., ÖZEN, S., GÖK, M., KÜÇÜKSÜMER, Y. (2017). Results of Dexamethasone Implant in the Treatment of Retinal Vein Occlussion Related Macular Edema. MN Oftalmoloji, Cilt: 24 - Sayı: 4, 226–231. https://ajindex.com/articles/295468

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Bayraktar MZ. Santral retinal ven oklüzyonu. T Klin J Ophthalmol 1993;21:51-56
  2. The Central Vein Occlusion Study Group M report. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. Ophthalmology 1995;102(10):1425-33
  3. Campa C, Alivernini G, Bolletta E, Parodi MB, Perri P. AntiVEGF Therapy for Retinal Vein Occlusions. Curr Drug Targets 2016;17(3):328-36
  4. Berger AR, Cruess AF, Altomare F, et al. Optimal Treatment of Retinal Vein Occlusion: Canadian Expert Consensus. Ophthal mo - logica 2015;234(1):6-25
  5. Moon J, Kim M, Sagong M. Combination therapy of intravitreal bevacizumab with single simultaneous posterior subtenon triamcinolone acetonide for macular edema due to branch retinal vein occlusion. Eye (Lond) 2016;30(8):1084-90
  6. Higham A, Jacob S, Cox M, et al. The efficacy and safety of intravitreal dexamethasone implants for macular oedema secondary to retinal vein occlusion: 3-year experience. Acta Ophthalmol 2016;94(7):674-5
  7. Karaçorlu M. Santral Retina Ven Dal Tıkanıklıklarında Tedavi. Ret-Vit 2004;12:233-7
  8. Eter N, Mohr A, Wachtlin J, et al. Dexamet hasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial. Graefes Arch Clin Exp Ophthalmol 2017;255(1):77-87
  9. Boyer DS, Yoon YH, Belfort R Jr, et al. Three-year, randomized,sham-controlled trialof dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014;121(10):1904-14
  10. Augustin AJ, Kuppermann BD, Lanzetta P, et al. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmol 2015;15:150
  11. Rezar S, Eibenberger K, Bühl W, et al. Anti-VEGF treatment in branch retinal vein occlusion:a real-world experience over 4 years. Acta Ophthalmol 2015;93(8):719-25
  12. Elbay A, Ozdemir H, Koytak A, Melikov A. Intravitreal Dexamethasone Implant for Treatment of Serous Macular Detachment in Central Retinal Vein Occlusion. J Ocul Pharmacol Ther 2017;33(6):473-9
  13. Calugaru D, Calugaru M. Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex) in its treatment. Graefes Arch Clin Exp Ophthalmol 2016;254(12):2477-8
  14. Patel A, Nguyen C, Lu S. Central Retinal Vein Occlusion: A Review of Current Evidence-based Treatment Options. Middle East Afr J Ophthalmol 2016;23(1):44-8
  15. Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual pr